Nicolet Advisory Services LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Nicolet Advisory Services LLC increased its holdings in Eli Lilly and Company by 16.0%, owning 3,814 shares valued at $3.15 million after acquiring an additional 527 shares in Q1.
• Analysts show a generally positive outlook, with the consensus rating at "Moderate Buy" and a target price of $1,012.56, despite some recent rating changes from firms like UBS Group and Erste Group Bank.
• Eli Lilly announced a quarterly dividend of $1.50 to be paid on September 10th, reflecting a 0.8% yield and a payout ratio of 48.82%.

Nicolet Advisory Services LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,814 shares of the company's stock after acquiring an additional 527 shares during the period. Nicolet Advisory Services LLC's holdings in Eli Lilly and Company were worth $3,150,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares during the period. Capital Research Global Investors grew its position in Eli Lilly and Company by 16.1% in the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after purchasing an additional 1,493,673 shares during the period. Northern Trust Corp grew its position in Eli Lilly and Company by 14.6% in the 4th quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock worth $7,294,025,000 after purchasing an additional 1,204,337 shares during the period. Capital International Investors grew its position in Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock worth $6,740,272,000 after purchasing an additional 1,645,222 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Eli Lilly and Company by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock worth $5,469,527,000 after purchasing an additional 969,376 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on LLY shares. UBS Group cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Price Performance

LLY stock traded up $21.40 during mid-day trading on Friday, hitting $761.47. The company had a trading volume of 4,857,388 shares, compared to its average volume of 3,285,034. The company has a market capitalization of $721.67 billion, a price-to-earnings ratio of 61.96, a P/E/G ratio of 1.05 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average price of $775.51 and a 200 day moving average price of $799.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.58 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.